{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:34Z","timestamp":1790983114329,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.lana.2026.101640","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:20:59Z","timestamp":1790241659000},"page":"101640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Risk of infection in ocrelizumab-treated adults with multiple sclerosis aged 55 years and older: a retrospective cohort study"],"prefix":"10.1016","volume":"64","author":[{"given":"Seungwon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3019-0805","authenticated-orcid":false,"given":"Raphael","family":"Scheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nomin","family":"Enkhtsetseg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9204-5196","authenticated-orcid":false,"given":"Joseph","family":"Sadok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3757-1587","authenticated-orcid":false,"given":"Maya","family":"Mastick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Satish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4293-8115","authenticated-orcid":false,"given":"Farrah J.","family":"Mateen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lana.2026.101640_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418773025","article-title":"Ocrelizumab: a new milestone in multiple sclerosis therapy","volume":"11","author":"Mulero","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1016\/j.lana.2026.101640_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lana.2026.101640_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lana.2026.101640_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","article-title":"Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice","volume":"180","author":"DiLillo","year":"2008","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.lana.2026.101640_bib5","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.23732","article-title":"Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.lana.2026.101640_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev.immunol.24.021605.090517","article-title":"B cell immunobiology in disease: evolving concepts from the clinic","volume":"24","author":"Martin","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.lana.2026.101640_bib7","series-title":"Roche Provides Update on Phase III OCREVUS High Dose Study in People with Relapsing Multiple Sclerosis","year":"2025"},{"key":"10.1016\/j.lana.2026.101640_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110266","article-title":"A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis","volume":"120","author":"Sabahi","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.lana.2026.101640_bib9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM Study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lana.2026.101640_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1379538","article-title":"Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review","volume":"15","author":"Fern\u00e1ndez","year":"2024","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.lana.2026.101640_bib11","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1007\/s00415-024-12384-3","article-title":"Management of multiple sclerosis in older adults: review of current evidence and future perspectives","volume":"271","author":"DiMauro","year":"2024","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.lana.2026.101640_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2020-000108","article-title":"Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study","volume":"3","author":"Smoot","year":"2021","journal-title":"BMJ Neurol Open"},{"key":"10.1016\/j.lana.2026.101640_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103798","article-title":"Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab","volume":"62","author":"Habek","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.lana.2026.101640_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102462","article-title":"Urinary tract infection in patients with multiple sclerosis: an overview","volume":"46","author":"Medeiros Junior","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.lana.2026.101640_bib15","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200164","article-title":"Multiple sclerosis, disease-modifying therapies, and infections","volume":"10","author":"Langer-Gould","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.lana.2026.101640_bib16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/cpt.3492","article-title":"Infection risk associated with high-efficacy disease-modifying agents in multiple sclerosis: a retrospective cohort study","volume":"117","author":"Li","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.lana.2026.101640_bib17","first-page":"115","article-title":"Infections in patients with multiple sclerosis treated with disease-modifying therapies: a comparative risk assessment cohort study","volume":"24","author":"Fattahi","year":"2025","journal-title":"Curr J Neurol"},{"issue":"6","key":"10.1016\/j.lana.2026.101640_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"13","key":"10.1016\/j.lana.2026.101640_bib19","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1177\/13524585251368687","article-title":"Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011\u20132021","volume":"31","author":"Li","year":"2025","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.lana.2026.101640_bib20","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lana.2026.101640_bib21","article-title":"Risk of serious infections in multiple sclerosis patients by disease course and disability status: results from a Swedish register-based study","volume":"22","author":"Brand","year":"2022","journal-title":"Brain Behav Immun Health"},{"key":"10.1016\/j.lana.2026.101640_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2023.1234572","article-title":"Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration","volume":"4","author":"Thakolwiboon","year":"2023","journal-title":"Front Aging"},{"issue":"6","key":"10.1016\/j.lana.2026.101640_bib23","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s10072-025-08018-9","article-title":"The relative risk of infection in people with multiple sclerosis using disease-modifying treatment: a systematic review of observational studies","volume":"46","author":"Leung","year":"2025","journal-title":"Neurol Sci"},{"issue":"8","key":"10.1016\/j.lana.2026.101640_bib24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41582-025-01115-5","article-title":"Advancing multiple sclerosis management in older adults","volume":"21","author":"Van Der Walt","year":"2025","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"10.1016\/j.lana.2026.101640_bib25","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1007\/s00415-022-11124-9","article-title":"Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients","volume":"269","author":"Einsiedler","year":"2022","journal-title":"J Neurol"},{"issue":"16","key":"10.1016\/j.lana.2026.101640_bib26","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.lana.2026.101640_bib27","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s00415-019-09690-6","article-title":"Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis","volume":"268","author":"Schweitzer","year":"2021","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.lana.2026.101640_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.lana.2026.101640_bib29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.lana.2026.101640_bib30","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"26","key":"10.1016\/j.lana.2026.101640_bib49","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1002\/sim.8355","article-title":"Avoiding pitfalls when combining multiple imputation and propensity scores","volume":"38","author":"Granger","year":"2019","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.lana.2026.101640_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/rssb.12027","article-title":"Covariate balancing propensity score","volume":"76","author":"Imai","year":"2014","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"10.1016\/j.lana.2026.101640_bib31","article-title":"Choosing the causal estimand for propensity score analysis of observational studies","author":"Greifer","year":"2021","journal-title":"arXiv"},{"key":"10.1016\/j.lana.2026.101640_bib33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jclinepi.2023.09.014","article-title":"The use of the E-value for sensitivity analysis","volume":"163","author":"Chung","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lana.2026.101640_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104400","article-title":"Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease","volume":"68","author":"Peters","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"10544","key":"10.1016\/j.lana.2026.101640_bib35","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(26)00617-3","article-title":"Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study","volume":"407","author":"Giovannoni","year":"2026","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lana.2026.101640_bib36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/da.20653","article-title":"Anxiety disorders in older adults: a comprehensive review","volume":"27","author":"Wolitzky-Taylor","year":"2010","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.lana.2026.101640_bib37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12991-021-00375-x","article-title":"Prevalence and determinants of depression among old age: a systematic review and meta-analysis","volume":"20","author":"Zenebe","year":"2021","journal-title":"Ann Gen Psychiatry"},{"issue":"7","key":"10.1016\/j.lana.2026.101640_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/jch.70093","article-title":"Hypertension prevalence, awareness, and control in US adults before and after the COVID-19 pandemic","volume":"27","author":"Essa","year":"2025","journal-title":"J Clin Hypertens"},{"issue":"2","key":"10.1016\/j.lana.2026.101640_bib39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.amepre.2024.04.010","article-title":"Trends and disparities in diabetes prevalence in the United States from 2012 to 2022","volume":"67","author":"Neupane","year":"2024","journal-title":"Am J Prev Med"},{"issue":"8","key":"10.1016\/j.lana.2026.101640_bib40","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","article-title":"Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: a retrospective cohort study","volume":"35","author":"Seery","year":"2021","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.lana.2026.101640_bib41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00415-025-13133-w","article-title":"Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis","volume":"272","author":"Davies","year":"2025","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.lana.2026.101640_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00537","article-title":"Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: a real-world, multi-center, propensity score-matched study","volume":"22","author":"Barbuti","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.lana.2026.101640_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1380654","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients","volume":"15","author":"Elgenidy","year":"2024","journal-title":"Front Neurol"},{"issue":"7_Supplement_1","key":"10.1016\/j.lana.2026.101640_bib45","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1212\/WNL.0000000000211332","article-title":"Severe neutropenia secondary to ocrelizumab: risk factors (P8-1.015)","volume":"104","author":"Barrera","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.lana.2026.101640_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106692","article-title":"Ocrelizumab-induced neutropenia in people with multiple sclerosis: a single-centre study","volume":"103","author":"Sartori","year":"2025","journal-title":"Mult Scler Relat Disord"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X2600270X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X2600270X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:05:19Z","timestamp":1790539519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X2600270X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":46,"alternative-id":["S2667193X2600270X"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2026.101640","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of infection in ocrelizumab-treated adults with multiple sclerosis aged 55 years and older: a retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2026.101640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101640"}}